Suppr超能文献

充血性心力衰竭患者医学管理的新观念

Newer concepts in the medical management of patients with congestive heart failure.

作者信息

Weintraub N L, Chaitman B R

机构信息

Department of Internal Medicine, Saint Louis University School of Medicine, Missouri 63110-0250.

出版信息

Clin Cardiol. 1993 May;16(5):380-90. doi: 10.1002/clc.4960160504.

Abstract

Congestive heart failure (CHF) remains a major cause of morbidity and mortality in the United States, especially among the elderly. Although an underlying disturbance in cardiac function can be identified in most patients, manifestations of the disease are greatly influenced by other factors, particularly neurohumoral and peripheral adaptive responses which occur secondary to impaired cardiac function. The renin-angiotensin system (RAS) is integrally involved in the pathophysiology of CHF. Originally considered a humoral system, the RAS is now known to exist and operate within cardiac and vascular tissues. The importance of tissue-specific renin-angiotensin systems in CHF is presently under investigation. Most patients with symptomatic CHF benefit from the administration of an ACE inhibitor. Certain asymptomatic patients, such as those with severe left ventricular (LV) dysfunction and those who are at high risk for LV remodeling after anterior wall myocardial infarction, may also benefit from ACE inhibitor therapy. Diuretics and nitrates improve symptoms and often cardiac output in many patients with CHF. Although many new inotropic agents have been tested in CHF patients, none appear clinically superior to digitalis glycosides. The efficacy of digitalis glycosides in CHF may in part result from sympathoinhibitory properties such as the activation of baroreceptor mechanisms. Despite the fact that many CHF patients die from arrhythmias, treatment of asymptomatic ventricular arrhythmias in these patients is not recommended. Patients with symptomatic or sustained ventricular arrhythmias are best treated by a physician experienced in cardiac electrophysiology. Therapy with beta-blocking drugs for CHF patients is controversial. Anticoagulants are recommended for selected patients with CHF. Finally, exercise therapy may improve functional capacity in some patients with CHF through its effects on peripheral blood vessels and skeletal muscle tissues.

摘要

在美国,充血性心力衰竭(CHF)仍然是发病和死亡的主要原因,在老年人中尤为如此。尽管大多数患者可发现潜在的心脏功能紊乱,但该疾病的表现会受到其他因素的显著影响,尤其是继发于心脏功能受损的神经体液和外周适应性反应。肾素 - 血管紧张素系统(RAS)全面参与了CHF的病理生理过程。RAS最初被认为是一种体液系统,现在已知其在心脏和血管组织中存在并发挥作用。目前正在研究组织特异性肾素 - 血管紧张素系统在CHF中的重要性。大多数有症状的CHF患者受益于ACE抑制剂的使用。某些无症状患者,如严重左心室(LV)功能障碍患者以及前壁心肌梗死后LV重塑高危患者,也可能从ACE抑制剂治疗中获益。利尿剂和硝酸盐可改善许多CHF患者的症状,并常常提高心输出量。尽管许多新型正性肌力药物已在CHF患者中进行了测试,但在临床上似乎没有一种优于洋地黄苷。洋地黄苷在CHF中的疗效可能部分源于其交感神经抑制特性,如压力感受器机制的激活。尽管许多CHF患者死于心律失常,但不建议对这些患者的无症状室性心律失常进行治疗。有症状或持续性室性心律失常的患者最好由有心脏电生理经验的医生进行治疗。CHF患者使用β受体阻滞剂治疗存在争议。推荐对选定的CHF患者使用抗凝剂。最后,运动疗法可能通过其对外周血管和骨骼肌组织的作用,改善一些CHF患者的功能能力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验